key: cord-0923903-ddwzr112
authors: Mishra, Ajay Kumar; Sahu, Kamal Kant; Sargent, Jennifer
title: Cardiac drugs and outcome in COVID - 19
date: 2020-04-14
journal: QJM
DOI: 10.1093/qjmed/hcaa127
sha: 139a7529a2b6605d3dbb70fe18c4876938ed3c4a
doc_id: 923903
cord_uid: ddwzr112

nan

Type: Letter to the editor Title: Cardiac drugs and outcome in COVID -19

We read with much interest the article "Are certain drugs associated with enhanced mortality in COVID -19" by Goldstein We agree with the authors that increase expression of ACE 2 receptor potentially increases viral entry and disease severity, however the data regarding only ARB's causing the same might not be enough. (6, 8) While awaiting further studies it would be prudent to discontinue ACE inhibitors, ARB's, and other RAAS antagonist on clinical ground as per the treating physician's discretion. (9) Though at present there is not enough evidence of any potential benefit or harm of most prescribed medications including the ARBs, ACEi, Statins, Antiviral agents we strongly agree with the authors that meticulous and detailed reporting of medications of COVID -19 affected patients is crucial in order to further understand the multifaceted interaction of the virus, medications, and clinical outcome.

Are certain drugs associated with enhanced mortality in COVID-19?

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Novel coronavirus (2019-nCoV): Update on 3 rd Coronavirus Outbreak of 21st Century

COVID-19 and the cardiovascular system

Angiotensin-converting enzyme 2: the first decade

COVID-19) and Cardiovascular Disease. Circulation

Randomized Controlled Trial of Losartan for Patients With OVID19 Not Requiring Hospitalization. Identifier: NCT04311177

Reporting of all cardiac medications and their outcome in COVID -19